PDF Report (2.3Mb)
View other formats
Cervical screening in Australia 2010-2011 presents the latest national statistics monitoring the National Cervical Screening Program, which aims to reduce incidence, morbidity and mortality from cervical cancer.
In 2011, for every 1,000 women screened, 8 women had a high-grade abnormality detected by histology
In 2010–2011, more than 3.6 million women participated in the NCSP. This was 57% of women in the target population
Only 13% of women with a negative Pap test in 2010 rescreened earlier than recommended
There was a clear trend of increasing participation with increasing socioeconomic status
The National Cervical Screening Program (NCSP) aims to reduce cervical cancer cases, as well as illness and death from cervical cancer in Australia, through an organised approach to cervical screening aimed at detecting and treating high-grade abnormalities before possible progression to cervical cancer. The target group is women aged 20-69.
This report is the latest in the Cervical screening in Australia series, which is published annually to provide regular monitoring of national participation and performance for the NCSP. While the previous report covered 2009-2010, this report provides data for the
2010-2011 period of participation in the NCSP, as well as the latest available cervical cancer incidence and mortality data (from sources outside the NCSP).
The following statistics refer to the latest data available for women aged 20-69.
There were 631 new cases diagnosed in 2009, and 152 women died from cervical cancer in 2010. This is equivalent to 9 new cases and 2 deaths per 100,000 women, respectively.
Incidence and mortality have both halved since the NCSP was introduced in 1991, remaining at their historic lows of 9 new cases and 2 deaths per 100,000 women since 2002.
The incidence of cervical cancer in Aboriginal and Torres Strait Islander women was more than twice that of non-Indigenous women, and mortality of Aboriginal and Torres Strait Islander women was 5 times the non-Indigenous rate.
In 2010-2011, more than 3.6 million women participated in the NCSP. This was 57% of women in the target population (after adjustment to exclude those without a cervix).
Participation was similar across remoteness areas, with the highest participation of 58% in Inner regional and the lowest of 55% in Remote areas.
There were greater differences in participation across socioeconomic status of residence, and a clear trend of increasing participation with increasing socioeconomic status from 52% in areas of lowest socioeconomic status to 63% in areas of highest socioeconomic status.
Participation by Aboriginal and Torres Strait Islander women is not available due to Indigenous status information not being collected on pathology forms, although there is evidence that this population group is under-screened.
Only 13% of women with a negative Pap test in 2010 rescreened earlier than recommended.
Of the women sent a 27-month reminder letter by a cervical cytology register in 2010,
32% rescreened within 3 months.
In 2011, for every 1,000 women screened, 8 women had a high-grade abnormality detected by histology, providing an opportunity for treatment before possible progression to cancer.
Peak high-grade abnormality detection was for women aged 25-29, a shift from the historic age group of 20-24, as a result of a decrease in high-grade abnormalities in younger women.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.